News

The FDA has granted a full approval to the combination use of pembrolizumab (Keytruda) plus standard chemotherapy in the first-line setting for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).

Canadian researchers recently created the Managing Cancer and Living Meaningfully (CALM) intervention for patients with advanced cancer who had a life expectancy of at least 1 year to address the need for supportive psychotherapy interventions that are individualized to the patient, brief, and easy to implement.

The addition of tumor treating fields (TTF), an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, to weekly paclitaxel (Taxol) appeared safe in the treatment of patients with platinum-resistant ovarian cancer.

The FDA has granted an accelerated approval to nivolumab (Opdivo) for the treatment of patients with small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy and 1 other line of therapy.

Enfortumab vedotin, an antibody-drug conjugate, showed promise as a post-immunotherapy treatment of patients with locally advanced or metastatic urothelial cancer, according to Jonathan E. Rosenberg, MD.

The Food and Drug Administration (FDA) approved a supplemental new drug application for the multikinase inhibitor lenvatinib (Lenvima) for first-line treatment of patients with unresectable hepatocellular carcinoma.

Late effects from treatment of central nervous system (CNS) tumors, such as cognitive impairment and physical performance, may hinder full functional and social independence among adult survivors, according to findings published in the Journal of Clinical Oncology.

Over the last few years, treatments for patients with metastatic hormone receptor (HR)-positive breast cancer have evolved rapidly. As changes in care continue to progress, nurses need to understand these treatment options, and where the research may take the field in the future.

The annual signature event has now raised more than $100 million for the V Foundation.

The FDA has granted a priority review designation to a biologics license application (BLA) for SL-401 (tagraxofusp, Elzonris) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to Stemline Therapeutics, the developer of the novel stemness inhibitor.

Men are reported to be less likely to receive palliative care, according to research led by Fahad Saeed, MD, from the University of Rochester Medical Center in Rochester, New York, and colleagues.

As abemaciclib (Verzenio) has emerged as a promising agent for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, the oncology nurse is now a key factor for these patients, according to Paula Fulgham, RN, OCN.

The favored use of immune checkpoint inhibitors in oncology has led to an increase in immune-related adverse events (IRAEs), which if not managed properly, can be life-threatening.

Distinguished nurse scientist, professor, and associate dean of research and scholarship leaves a lasting legacy.

CURE magazine, the nation’s leading consumer digital and print media enterprise focused on patients with cancer, was recently named a finalist in four categories in the Folio: Eddie and Ozzie Awards, the most prestigious and most inclusive awards program in the publishing community.

The FDA has approved the monoclonal antibody mogamulizumab-kpkc (Poteligeo) for the treatment of patients with 2 rare subtypes of cutaneous T-cell lymphoma, mycosis fungoides or Sézary syndrome, who have received at least 1 prior systemic therapy.

The FDA has granted breakthrough therapy designation to a triplet combination regimen, which would expedite the development and review of the first treatment for BRAFV600E–mutant metastatic colorectal cancer (mCRC).

Survival rates of patients diagnosed with mantle cell lymphoma (MCL) have nearly doubled thanks to improvements in the treatment landscape over the past 10 years.

Significant weight loss, increased blood glucose levels, and older age at onset of diabetes may be useful in determining the risk of pancreatic cancer in people newly diagnosed with diabetes.

A recent review of data found that 79% of patients with ovarian cancer felt uncomfortable raising psychological and emotional concerns during their consultations.

Sharon Mitchell, RN, stood up for her profession at Pennsylvania’s first-ever Nurses Safe Staffing Summit in Harrisburg, Pennsylvania on July 30-31, speaking and participating in an event to draw attention to safe staffing bills.

The FDA has granted a second breakthrough therapy designation to the combination use of lenvatinib (Lenvima) and pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy.

In a phase 1 clinical trial, researchers injected a genetically altered version of the poliovirus into glioblastoma tumors.

Check out the top 5 Oncology Nursing News stories for July 2018 in this video recap.

The FDA has approved iobenguane I-131 (Azedra) for adult and pediatric patients 12 years and older with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy.

The Leukemia & Lymphoma Society (LLS) is known for its assistance to patients, but did you know that this organization also offers many resources for clinicians as well?

Physicians’ Education Resource (PER)® set to host 2nd Annual School of Nursing Oncology™ from August 3 through 4 in Chicago.

The event recognizes individuals dedicated to empowering people affected by myeloproliferative neoplasms.